As genome editing therapies move through clinical trials to regulatory approval, scientists continue the quest for the holy ...

The infrastructure moment for AI-driven drug discovery continues to accelerate, with billion-dollar investments flowing into ...

New biotech stock Kardigan may reveal Wall Street’s next move ...

In an interview, synthetic biologist Peter Carr explains research on synthetic cells, their potential benefits and hazards, ...

Artificial intelligence is reshaping nearly every industry, but some of its biggest opportunities are emerging far from ...

Background The ocean harbors an immense, largely untapped diversity of microorganisms—bacteria, fungi, yeasts, thraustochytrids, and microalgae—whose ...

For most of the past three years, Jim Cramer kept his distance from Moderna, treating the biotech stock with skepticism ...

On a YouTube livestream, Berkeley City College students carefully study the movements of stem cells to observe what they do ...

This cell-like structure can grow, feed, divide and compete. Researchers ponder what it means for the future of synthetic ...

The decision supports stronger international participation, enhanced business opportunities and an impactful launch edition for the region's process industries, directly supporting Vision 2030's ...

Yes, many of the companies you've invested in also have their own stock portfolios. This is bullishness worth noting.

Patented platform uses cell-free DNA analysis and machine learning to detect cancer early and identify tissue of origin from ...